Search

Your search keyword '"Cornelissen, Jan J"' showing total 1,443 results

Search Constraints

Start Over You searched for: Author "Cornelissen, Jan J" Remove constraint Author: "Cornelissen, Jan J"
1,443 results on '"Cornelissen, Jan J"'

Search Results

2. Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT

3. Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

4. AML in Adults

6. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

7. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT

9. Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

10. Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT

11. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer

12. Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study

15. Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT

16. Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

19. Time‐restricted versus standard‐duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON‐96 trial.

20. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

21. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial

22. HEV infection in stem cell transplant recipients—retrospective study of EBMT Infectious Diseases Working Party

23. BCR::ABL1Deep Molecular Response Quantification and Transcript Type Identification in Chronic Myeloid Leukemia Using a US Food and Drug Administration–Approved Droplet-Based Digital PCR Assay

24. Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT

25. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT

26. Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP–EBMT

27. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.

30. BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis

31. Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?

32. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling

33. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study

34. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study

35. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

36. Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: Does it influence survival?

37. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling

38. Regional disparities in the use of intensive chemotherapy for AML in the Netherlands:Does it influence survival?

39. Cord blood transplantation for adult lymphoid neoplasms in Europe and Japan

40. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling

41. Bayesian interim analysis for prospective randomized studies:reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

42. Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status

43. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

44. Acute Myeloid Leukemia in Adults

45. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

46. Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

49. HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis

Catalog

Books, media, physical & digital resources